JP7633179B2 - 神経保護のためのカンナビノイドの組成物及び使用方法 - Google Patents

神経保護のためのカンナビノイドの組成物及び使用方法 Download PDF

Info

Publication number
JP7633179B2
JP7633179B2 JP2021563360A JP2021563360A JP7633179B2 JP 7633179 B2 JP7633179 B2 JP 7633179B2 JP 2021563360 A JP2021563360 A JP 2021563360A JP 2021563360 A JP2021563360 A JP 2021563360A JP 7633179 B2 JP7633179 B2 JP 7633179B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
neuroprotective
neuroprotective compound
cannabinol
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021563360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530471A (ja
JP2022530471A5 (https=
Inventor
シュー エリック
クマール ウジェンドラ
クマール ソムバンシ リシ
ツォウ ションロン
Original Assignee
インメド ファーマシューティカルズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インメド ファーマシューティカルズ インコーポレイティド filed Critical インメド ファーマシューティカルズ インコーポレイティド
Publication of JP2022530471A publication Critical patent/JP2022530471A/ja
Publication of JP2022530471A5 publication Critical patent/JP2022530471A5/ja
Application granted granted Critical
Publication of JP7633179B2 publication Critical patent/JP7633179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021563360A 2019-04-24 2020-04-24 神経保護のためのカンナビノイドの組成物及び使用方法 Active JP7633179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838216P 2019-04-24 2019-04-24
US62/838,216 2019-04-24
PCT/CA2020/050547 WO2020215164A1 (en) 2019-04-24 2020-04-24 Compositions and methods for use of cannabinoids for neuroprotection

Publications (3)

Publication Number Publication Date
JP2022530471A JP2022530471A (ja) 2022-06-29
JP2022530471A5 JP2022530471A5 (https=) 2023-05-02
JP7633179B2 true JP7633179B2 (ja) 2025-02-19

Family

ID=72940570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563360A Active JP7633179B2 (ja) 2019-04-24 2020-04-24 神経保護のためのカンナビノイドの組成物及び使用方法

Country Status (11)

Country Link
US (1) US20230043428A1 (https=)
EP (1) EP3958856A4 (https=)
JP (1) JP7633179B2 (https=)
KR (1) KR20220080045A (https=)
CN (1) CN114007603A (https=)
AU (1) AU2020261515B2 (https=)
CA (1) CA3134764A1 (https=)
IL (1) IL287536B2 (https=)
MX (1) MX2021012960A (https=)
SG (1) SG11202111809XA (https=)
WO (1) WO2020215164A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115006404A (zh) * 2022-08-09 2022-09-06 昆药集团股份有限公司 一种具有视神经保护功效的药物组合物及其应用
WO2024091653A1 (en) * 2022-10-27 2024-05-02 Kemin Industries, Inc. Use of a spearmint extract for retina neurotrophism
WO2024148117A2 (en) * 2023-01-04 2024-07-11 Florascience Inc. Methods of treating neurodegenerative diseases or conditions
WO2025090133A1 (en) * 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535539A (ja) 2014-10-21 2017-11-30 ユナイテッド カナビス コーポレイション 大麻抽出物ならびにその調製方法および使用方法
US20180098948A1 (en) 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018205038A1 (en) 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling
WO2018205022A1 (en) 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2471987B (en) * 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2640379A4 (en) * 2010-11-18 2014-08-13 Pier Pharmaceuticals LOW DOSED CANNABINOIDARY MEDICINES
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20160282371A1 (en) * 2015-03-28 2016-09-29 Quantalytical Labs Inc. Solid Phase Extraction, Derivatization with Crown Ethers, and Mass Spectrometry, Methods, Reagents and Kits
IL248149B (en) * 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
US20170348277A1 (en) * 2017-08-02 2017-12-07 Bryan Ray Ruiz Cannabinoid formulation including a vasodilator and ocular delivery of the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017535539A (ja) 2014-10-21 2017-11-30 ユナイテッド カナビス コーポレイション 大麻抽出物ならびにその調製方法および使用方法
US20180098948A1 (en) 2016-10-11 2018-04-12 Growblox Life Sciences L.L.C. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
WO2018205022A1 (en) 2017-05-08 2018-11-15 Inmed Pharmaceuticals Inc. Ocular drug delivery formulation
WO2018205038A1 (en) 2017-05-12 2018-11-15 Tetra Bio-Pharma Inc. Compositions comprising cannabinoids and terpenes useful in the treatment of cancer and vascular ocular disorders via inhibition of hedgehog signalling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery，Drug Delivery and Translational Research，2018年，8，484-495，https://doi.org/10.1007/s13346-018-0504-x
Cannabinoids in Glaucoma: A Primary Screening Procedure，J Clin Pharmacol.，1981年，21，pp.472S-478S

Also Published As

Publication number Publication date
IL287536A (en) 2021-12-01
AU2020261515A1 (en) 2021-11-18
WO2020215164A1 (en) 2020-10-29
EP3958856A4 (en) 2023-01-25
IL287536B2 (en) 2026-03-01
US20230043428A1 (en) 2023-02-09
SG11202111809XA (en) 2021-11-29
IL287536B1 (en) 2025-11-01
JP2022530471A (ja) 2022-06-29
AU2020261515B2 (en) 2025-10-23
KR20220080045A (ko) 2022-06-14
EP3958856A1 (en) 2022-03-02
CN114007603A (zh) 2022-02-01
MX2021012960A (es) 2022-01-04
CA3134764A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
JP7633179B2 (ja) 神経保護のためのカンナビノイドの組成物及び使用方法
KR20100016140A (ko) 가령 황반 변성의 예방 또는 치료제
EP2852383A2 (en) Methods for drug screen using zebrafish model and the compounds screened thereform
JP2004518612A (ja) インドール誘導体を用いて眼圧を下降させる方法
JP7636742B2 (ja) 制御送達性クロマカリムプロドラッグ
ES2348314T3 (es) Derivados de mononitrato de isosorbida para el tratamiento de la hipertensión ocular.
US20040087664A1 (en) Methods and compositions for treatment of macular and retinal disease
CN101102770A (zh) 白内障、黄斑变性和其它眼科疾病的改善
CN117136050A (zh) 用于使用大麻素治疗神经元病症的组合物和方法
EP2170343A1 (en) Treatment of age-related macular degeneration
CA3087019A1 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
WO2025090133A1 (en) Compositions and methods for use of cannabinol compounds in neuroprotection
US20150284393A1 (en) Methods for treating eye disorders
US20080318939A1 (en) Methods for treating ophthalmic disorders
WO2025090587A1 (en) Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2009110526A1 (ja) ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
EA051012B1 (ru) Соединения, являющиеся антагонистами trpa1 каналов, для применения при дегенеративных заболеваниях сетчатки
TW202523286A (zh) 立汎黴素（ｒｉｆａｍｙｃｉｎ）的眼用組成物及其用途
WO2022249942A1 (ja) 網膜の神経細胞の保護剤
JP2023547412A (ja) 眼疾患の治療
WO2020166679A1 (ja) 眼圧下降用医薬組成物
Kobayashi et al. 152. Neuroprotection Organizing Section: PH Contributing Section: RC
CA3014071A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
HK1241269B (zh) 前列腺素类和一氧化氮供体的组合产品

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230424

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250206

R150 Certificate of patent or registration of utility model

Ref document number: 7633179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150